Michael J Fossler - JoVE Visualize

Showing results (41-50 of 47) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 47 results.

Pain and Therapy|November 19, 2020

Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled TrialsTimothy L Beard, Cathy Michalsky, Keith A Candiotti, et al.

Antimicrobial Agents and Chemotherapy|June 30, 2016

Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting MethodsYanhui Lu, Vineet Goti, Ayyappa Chaturvedula, et al.

Cancer Chemotherapy and Pharmacology|April 10, 2008

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adultsDivya Menon-Andersen, John T Mondick, Bhuvana Jayaraman, et al.

Clinical Pharmacology in Drug Development|May 21, 2016

Relative Bioavailability of an Emulsion Formulation for Omega-3-Acid Ethyl Esters Compared to the Commercially Available Formulation: A Randomized, Parallel-Group, Single-Dose Study Followed by Repeat Dosing in Healthy VolunteersElizabeth K Hussey, Samm Portelli, Michael J Fossler, et al.

The AAPS Journal|August 3, 2013

A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage formsAnne Zajicek, Michael J Fossler, Jeffrey S Barrett, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2002

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysisJames W Hainer, Donald J Sherrard, Suzanne K Swan, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2007

Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humansMingxin Qian, Stephen A Bai, Bernice Brogdon, et al.

Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 47 results.

Pain and Therapy|November 19, 2020

Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled TrialsTimothy L Beard, Cathy Michalsky, Keith A Candiotti, et al.

Antimicrobial Agents and Chemotherapy|June 30, 2016

Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting MethodsYanhui Lu, Vineet Goti, Ayyappa Chaturvedula, et al.

Cancer Chemotherapy and Pharmacology|April 10, 2008

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adultsDivya Menon-Andersen, John T Mondick, Bhuvana Jayaraman, et al.

Clinical Pharmacology in Drug Development|May 21, 2016

Relative Bioavailability of an Emulsion Formulation for Omega-3-Acid Ethyl Esters Compared to the Commercially Available Formulation: A Randomized, Parallel-Group, Single-Dose Study Followed by Repeat Dosing in Healthy VolunteersElizabeth K Hussey, Samm Portelli, Michael J Fossler, et al.

The AAPS Journal|August 3, 2013

A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage formsAnne Zajicek, Michael J Fossler, Jeffrey S Barrett, et al.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2002

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysisJames W Hainer, Donald J Sherrard, Suzanne K Swan, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2007

Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humansMingxin Qian, Stephen A Bai, Bernice Brogdon, et al.

Pageof 5